Bold claim: GLP-1 weight‑loss drugs are redefining obesity treatment and shaking up the global pharmaceutical market. But the real story isn’t just science—it’s the price tag, the insurance hurdles, and who ultimately pays.
GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro began as treatments for type 2 diabetes. Today they’re widely prescribed for weight loss and are backed by growing evidence that they can also lower the risk of heart disease and stroke. Yet in the United States, access to these medications often hinges on what insurance covers and who can afford the out‑of‑pocket costs.
In this opening episode of a three‑part Business Daily series on the global weight‑loss economy, Sam Fenwick investigates the true cost of obesity drugs within the U.S. healthcare system.
Key questions explored include:
- How much do GLP‑1 medications actually cost (for drugs like Ozempic, Wegovy, Zepbound, and Mounjaro)?
- Are they cost‑effective over the long term?
- Can insurers and employers sustain offering them to millions of Americans living with obesity?
If you’d like to reach the team, you can email businessdaily@bbc.co.uk.
Produced and presented by Sam Fenwick, Business Daily delivers in‑depth audio journalism focused on money and work. Each 17‑minute episode dives into a single topic with expert analysis and voices from the people at the center of the story.
Recent episodes examine the weight‑loss drug revolution, the rise of AI, the cost of living, the power of bond markets, China’s property sector, and Gen Z’s experience in today’s job market. We also feature interviews with startup founders and top global CEOs, including Sundar Pichai (Google), Jimmy Wales (Wikipedia), Melanie Perkins (Canva), and Brian Niccol (Starbucks).
(Picture: Person standing on weighing scales. Credit: Press Association)
